The US neurological disorder drugs market is projected to grow at a significant CAGR during the forecast period (2020-2026). The rising prevalence of neurological disorders coupled with the rising geriatric population tends to drive the growth of the market. In addition, the launch of novel products by the key players across the globe further supports the growth of the market. For instance, in December 2019, Ubrelvy, a novel drug manufactured by Allergan Plc was approved by the US FDA for the treatment of neurological disorders including migraine. With the introduction of a novel drug, the company strengthened its product portfolio. 

Visit for Global Neurological Disorder Drugs Market Report at: https://www.omrglobal.com/industry-reports/neurological-disorder-drugs-market

The US neurological disorder drugs market is segmented on the basis of disorder type into Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, Huntington disease, and others. Amongst the disorder type segment, Parkinson’s disease segment is projected to hold a lucrative share in the market. The segmental growth of the market is attributed to the increased prevalence of Parkinson’s disease among people across the globe. A broad range of drugs is used for the treatment of neurological disorders, some of which include analgesics, antihypertensive, anticholinergic, hypnotic & sedatives, and others. 

Further, Eli Lilly and Co., Merck & Co. Inc., Abbvie Inc., Apotex Inc., AstraZeneca Plc, Pfizer Inc., Biogen Inc., and Amgen Inc. are some of the prominent players functioning in the US neurological disorder drugs market. New product launches & developments, partnerships, agreements, and acquisitions are some of the growth strategies adopted by the players to sustain in the highly competitive market. 

Research Methodology

The market study of the US neurological disorder drugs market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of our reports.

Secondary Sources Include:

• Financial reports of companies involved in the market
• Whitepapers, research-papers, and news blogs
• Company websites and their product catalog

The report is intended for the pharmaceutical industry, drug manufacturers, hospitals & clinics, research organizations, academic institutes, non-profit organizations, government organizations, regulatory bodies, and other market participants for overall market analysis and competitive analysis. The report provides an in-depth analysis of the market size and growth opportunities. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for better business decisions.

Market Segmentation:

1. US Neurological Disorder Drugs Market Research and Analysis by Disorder Type

The Report covers:

• Comprehensive research methodology of the US Neurological Disorder Drugs market.
• This report also includes a detailed and extensive market overview with key analyst insights.
• An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
• Analysis of regional regulations and other government policies impacting the US Neurological Disorder Drugs market.
• Insights about market determinants which are stimulating the US Neurological Disorder Drugs market.
• Detailed and extensive market segments with regional distribution of forecast revenues.
• Extensive profiles and recent developments of the market players.